Chief Commercial Officer-CLIA John Leite executed a sale of 5,479 shares of Veracyte Inc (VCYT, Financial) on September 4, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 76,174 shares of the company. The shares were sold at a price of $29.78, valuing the transaction at approximately $163,194.62.
Veracyte Inc specializes in genomic diagnostics and is focused on improving patient outcomes by providing answers that guide clinical decisions in areas such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.
Over the past year, John Leite has sold a total of 6,756 shares and has not made any purchases of the company's stock. This recent transaction follows a pattern observed over the last year, where there have been 14 insider sells and no insider buys at Veracyte Inc.
The company's shares were trading at $29.78 on the day of the transaction, giving the company a market cap of approximately $2.19 billion. According to the GF Value, the intrinsic value estimate for Veracyte Inc is $31.33 per share, suggesting that the stock is Fairly Valued with a price-to-GF-Value ratio of 0.95.
The GF Value is determined by considering historical valuation multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from analysts.
This insider sale might be of interest to investors tracking insider behaviors and company valuation metrics to inform their investment decisions in Veracyte Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
